AZD-6280

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H22N4O3
Molecular Weight	366.4137
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCNC(=O)C1=NN=C2C(=CC=CC2=C1N)C3=CC(OC)=CC=C3OC

InChI

InChIKey=NVWCZRPXYVDQEE-UHFFFAOYSA-N

InChI=1S/C20H22N4O3/c1-4-10-22-20(25)19-17(21)14-7-5-6-13(18(14)23-24-19)15-11-12(26-2)8-9-16(15)27-3/h5-9,11H,4,10H2,1-3H3,(H2,21,23)(H,22,25)

HIDE SMILES / InChI

Molecular Formula	C20H22N4O3
Molecular Weight	366.4137
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25493397 | https://adisinsight.springer.com/drugs/800027607

AZD6280 was invented by AstraZeneca as a selective gamma-aminobutyric acid A receptor modulator with higher efficacy at the α2,3 subtypes (GABA-A(α2/3)). This drug participated in trials phase I for the treatment of generalized anxiety disorders, but AstraZeneca discontinued development of AZD 6280.

Originator

Approval Year

PubMed

Title	Date	PubMed
Absorption, excretion, and metabolism of a potential GABA-A α2/3 receptor modulator in rats.	2011 May	21210737

Patents

Sample Use Guides

In Vivo Use Guide

Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:43:32 GMT 2023` Edited by `admin` on `Sat Dec 16 01:43:32 GMT 2023`
Record UNII	B9Z1OEH19D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-6280

Common Name

English

3-CINNOLINECARBOXAMIDE, 4-AMINO-8-(2,5-DIMETHOXYPHENYL)-N-PROPYL-

Systematic Name

English

AZD6280

Code

English

Code System Code Type Description

EPA CompTox

DTXSID60915944